STOCK TITAN
  1. Home
  2. News
  3. HROW

Harrow, Inc. - HROW STOCK NEWS

Welcome to our dedicated page for Harrow news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow stock.

Harrow Health, Inc. (NASDAQ: HROW) is a leading eyecare pharmaceutical company dedicated to developing, producing, and distributing medications that address unmet medical needs, primarily within the United States. The company’s core business revolves around the creation of ophthalmology-based formulations, providing both sterile and non-sterile compounded medications to physicians and patients.

Harrow Inc. is at the forefront of innovative therapeutics, focusing on the treatment of ocular surface diseases. The firm's product portfolio includes prominent drug candidates such as SURF-100 and SURF-200, which are topical eye drops; SURF-300, an oral capsule aimed at treating ocular surface diseases and dry eye disease (DED) symptoms; and Klarity drops, designed for the protection and rehabilitation of ocular surface pathology in DED patients.

Additionally, Harrow, Inc. is known for its non-intravenous sedation and anesthesia products for various medical procedures. MELT-100, for instance, is a sublingual drug facilitating conscious sedation during cataract surgery, and MAY-66 is utilized for alleviating symptoms associated with Peyronie’s disease.

Harrow Health's commitment goes beyond innovation; it strives to improve accessibility and affordability of eyecare pharmaceuticals for millions of Americans. Through strategic partnerships and ongoing projects, Harrow, Inc. continues to enhance its capabilities in the eyecare sector, firmly positioning itself as a trusted name among U.S. eyecare professionals.

Stay updated with the latest developments, financial reports, and news on Harrow, Inc. to understand how this company is shaping the future of ophthalmic care.

News

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

Rhea-AI Summary
Melt Pharmaceuticals enters exclusive development and license agreement with Catalent for MELT-300, a sublingual formulation for procedural sedation during cataract surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
-
News

Harrow Announces Second Quarter 2023 Financial Results

Rhea-AI Summary
Harrow announces record revenues of $33.5 million, a 44% increase YoY, and a net loss of ($4.2) million. Also reports record adjusted EBITDA of $11.0 million, a 144% increase YoY. Completed public offering of common stock for $69 million. Acquired commercial rights to several drugs. Expanded Oaktree Loan to $112.50 million. Positive financial performance and acquisitions may positively impact stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.45%
Tags
earnings
-
News

Harrow Launches VIGAMOX® in the U.S.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
News

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
earnings
-
News

Harrow Prices $60 Million Public Offering of Common Stock

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
offering
-
News

Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America

Rhea-AI Summary
Santen Pharmaceutical Co., Ltd. (Santen) has signed licensing agreements with Visiox Pharmaceuticals, Inc. and Harrow Health, Inc. for the out-licensing of OMLONTI® and the transfer of various eye drop products. This includes exclusive rights for product manufacturing, commercialization, and sales in the U.S. and Canada, with potential royalty payments for Santen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
none
News

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

Rhea-AI Summary
Harrow (Nasdaq: HROW) Acquires U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, FRESHKOTE®, and Cationorm® PLUS from Santen Pharmaceutical Co., Ltd. The acquisition aims to enhance Harrow's position in the U.S. ophthalmic pharmaceutical market, broadening its branded portfolio and offering high utility and trusted products for ophthalmic surgical and dry eye symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
acquisition
-
News

Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
earnings
-
News

Harrow Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
offering
News

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
acquisition

FAQ

What is the current stock price of Harrow (HROW)?

The current stock price of Harrow (HROW) is $36.02 as of January 7, 2025.

What is the market cap of Harrow (HROW)?

The market cap of Harrow (HROW) is approximately 1.3B.

What does Harrow, Inc. specialize in?

Harrow, Inc. specializes in developing, producing, and selling ophthalmic pharmaceutical products and compounded medications for unmet medical needs in the U.S.

What are some key products of Harrow, Inc.?

Key products include SURF-100, SURF-200, SURF-300, Klarity drops, MELT-100, and MAY-66, which cater to various ocular surface diseases and medical procedures.

What is the significance of SURF-300?

SURF-300 is an oral capsule designed to treat patients suffering from ocular surface diseases and symptoms of dry eye disease (DED).

How does MELT-100 benefit patients?

MELT-100 is administered sublingually for conscious sedation during cataract surgery, providing a non-intravenous sedation option.

Who are the primary customers of Harrow, Inc.?

The primary customers are U.S. eyecare professionals and their patients, benefiting from Harrow, Inc.'s comprehensive portfolio of affordable pharmaceutical products.

What makes Harrow, Inc. unique in the eyecare pharmaceutical sector?

Harrow, Inc. stands out due to its focus on unmet medical needs, innovative product portfolio, and commitment to accessibility and affordability in the ophthalmic care market.

How does Harrow, Inc. contribute to the treatment of dry eye disease (DED)?

Products like SURF-300 and Klarity drops are specifically designed to treat and manage symptoms of dry eye disease, protecting and rehabilitating the ocular surface.

Where is Harrow, Inc. based?

Harrow, Inc. operates primarily in the United States, serving the American market with its pharmaceutical innovations.

What recent achievements has Harrow, Inc. made?

Recent achievements include the development and commercialization of various therapeutics for ocular surface diseases and advancements in non-intravenous sedation products.

How can investors stay updated with Harrow, Inc.'s latest news?

Investors can stay updated by following financial reports, press releases, and news updates provided by the company and credible financial news sources.
Stock HROW logo
Harrow, Inc.

Nasdaq:HROW

HROW Rankings

#2359 Ranked by Market Cap
N/A Ranked by Dividends

HROW Stock Data

1.27B
30.81M
13.49%
59.29%
8.33%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NASHVILLE